Edition:
United States

Bio Rad Laboratories Inc (BIO.N)

BIO.N on New York Stock Exchange

230.89USD
21 Sep 2017
Change (% chg)

$-2.26 (-0.97%)
Prev Close
$233.15
Open
$232.64
Day's High
$232.64
Day's Low
$230.00
Volume
31,998
Avg. Vol
34,710
52-wk High
$242.58
52-wk Low
$154.89

Latest Key Developments (Source: Significant Developments)

Bio-Rad reports Q2 earnings per share $0.17
Thursday, 3 Aug 2017 04:42pm EDT 

Aug 3 (Reuters) - Bio Rad Laboratories Inc -:Bio-Rad reports second-quarter 2017 financial results.Q2 earnings per share $0.17.Q2 sales $504.7 million versus i/b/e/s view $515.8 million.Q2 earnings per share view $0.56 -- Thomson Reuters I/B/E/S.Bio Rad Laboratories Inc - for full year 2017, company continues to anticipate currency-neutral organic sales growth of approximately 4 percent,.Bio Rad Laboratories - lowering estimate for currency-neutral operating profit for fy2017 from 7 percent of sales to now be in 6 to 6.5 percent range​.Bio Rad Laboratories Inc - ‍addition of recently acquired raindance technologies could add up to another 1 percent of growth in sales for FY 2017​.  Full Article

Bio Rad Laboratories receives FDA clearance for Bioplex 2200 syphilis total & RPR assay​
Monday, 12 Jun 2017 08:30am EDT 

June 12 (Reuters) - Bio Rad Laboratories Inc ::Bio Rad Laboratories Inc - ‍has received U.S. Food and Drug Administration clearance for its Bioplex 2200 syphilis total & RPR assay​.  Full Article

Bio-Rad Laboratories reports Q1 earnings per share $0.41
Thursday, 4 May 2017 04:15pm EDT 

May 4 (Reuters) - Bio-Rad Laboratories Inc :Bio-Rad reports first-quarter 2017 financial results.Q1 earnings per share $0.41.Q1 revenue $500.1 million versus I/B/E/S view $477.8 million.Q1 earnings per share view $0.30 -- Thomson Reuters I/B/E/S.Bio-Rad Laboratories Inc - for full year 2017, company continues to anticipate currency neutral revenue growth of approximately 4 percent.  Full Article

Bio Rad Laboratories Inc says expects to achieve long-term currency-neutral revenue growth of approximately 3% to 5%
Monday, 13 Mar 2017 08:31am EDT 

Bio Rad Laboratories Inc : Bio Rad Laboratories Inc says expects to achieve long-term currency-neutral revenue growth of approximately 3% to 5% . Bio Rad Laboratories Inc says expects to achieve currency-neutral EBITDA margin of greater than 20% by 2020 . Bio Rad Laboratories Inc says reiterated its 2017 financial outlook .FY2017 earnings per share view $2.80, revenue view $2.11 billion -- Thomson Reuters I/B/E/S.  Full Article

Bio Rad Laboratories reports Q2 profit $0.61 per share
Wednesday, 3 Aug 2016 04:15pm EDT 

Bio Rad Laboratories Inc : Second-Quarter reported revenues were $516.8 million, an increase of 2.1 percent . Bio-Rad reports second-quarter 2016 financial results .Net income for Q2 of 2016 was $18.0 million, or $0.61 per share.  Full Article

Bio-Rad Laboratories Inc's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Monday, 21 Dec 2015 04:21pm EST 

Bio-Rad Laboratories:Received U.S. Food and Drug Administration clearance to market its TANGO infinity system in the U.S.The system automates routine blood typing and screening testing procedures for patients and donors.  Full Article

BRIEF-U.S. ITC to probe certain 10X Genomics devices after Bio-Rad complaint

* U.S. U.S. International Trade Commission says it will investigate certain microfluidic devices by 10x Genomics Inc after complaint by Bio-rad Laboratories Inc and Lawrence Livermore National Security LLC. Source text for Eikon: Further company coverage: (Reporting By Susan Heavey)